NDA 007335 · Apothecon
Pronestyl
Procainamide Hydrochloride · Oral, Injection
NovelPriority reviewDiscontinuedLast checked: Nov 19, 2026Latest source record: Mar 13, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1950
Jun 2, 1950
Approved uses
3
Original approval plus efficacy supplements
Registered trials
12
5 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 13, 2009 Supplement 31 · Efficacy
- Oct 3, 1991 Supplement 58 · Efficacy
- Jun 2, 1950 Original approval · Type 1 - New Molecular Entity · priority review
5 products under this application
- PRONESTYL · PROCAINAMIDE HYDROCHLORIDE 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- PRONESTYL · PROCAINAMIDE HYDROCHLORIDE 375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- PRONESTYL · PROCAINAMIDE HYDROCHLORIDE 100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- PRONESTYL · PROCAINAMIDE HYDROCHLORIDE 500MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- PRONESTYL · PROCAINAMIDE HYDROCHLORIDE 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Procainamide" as an intervention, any sponsor and status, largest first.
- Prevention of Post-Operative Cardiac ArrhythmiasPivotal-lookingStatus unknown
Jeffrey MoakAcademic, hospital or other
NCT04234906 · 870 participants (planned) · Start Jan 2023 · Primary completion Apr 2023
Drug: Dexmedetomidine; Magnesium Sulfate and 2 more · For: Cardiac; Dysrhythmia, Postoperative; Congenital Heart Surgery
- RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency DepartmentPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04485195 · 350 participants · Start Jun 17, 2021 · Primary completion Sep 15, 2024
Drug: Vernakalant; Procainamide · For: Atrial Fibrillation
Sites: Edmonton, Canada; Vancouver, Canada; Halifax, Canada · 14 sites in all
- Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular TachycardiaPivotal-lookingTerminated
Hospital General Universitario Gregorio MarañonAcademic, hospital or other
NCT00383799 · 302 participants · Start Sep 2005 · Primary completion Jun 2011
Drug: iv Amiodarone; iv Procainamide · For: Ventricular Tachycardia; Wide QRS Tachycardia
Sites: El Escorial, Spain; Getafe, Spain; Cartagena, Spain · 29 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT01205529 · 161 participants · Start Nov 2010 · Primary completion Jun 2015
Drug: Procainamide · For: Atrial Fibrillation
Sites: Nashville, Tennessee
- Ajmaline Utilization in the Diagnosis and Treatment of Cardiac ArrhythmiasPivotal-lookingCompleted
Hospital Clinic of BarcelonaAcademic, hospital or other
NCT00702117 · 123 participants · Start Jun 2008 · Primary completion Jan 2010
Drug: flecainide; ajmaline and 1 more · For: Atrial Fibrillation; Tachycardia, Ventricular; Brugada Syndrome
Sites: Barcelona, Spain; Donostia / San Sebastian, Spain; Madrid, Spain · 4 sites in all
- Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial FibrillationPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT01994070 · 86 participants · Start Nov 2013 · Primary completion Mar 2015
Drug: Electrical-first; Chemical-first · For: Atrial Fibrillation
Sites: Vancouver, Canada
- AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot StudyPivotal-lookingTerminated
Mayo ClinicAcademic, hospital or other
NCT00589303 · 27 participants · Start Dec 2007 · Primary completion Jul 2011
Drug: FDA approved rate and rhythm control drugs · For: Atrial Fibrillation; Heart Failure
Sites: Scottsdale, Arizona; Evansville, Indiana; Rochester, Minnesota · 6 sites in all
- Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock PreventionTerminated
Ottawa Heart Institute Research CorporationAcademic, hospital or other
NCT02114528 · 3 participants · Start Oct 2014 · Primary completion Nov 2015
Drug: Antiarrhythmic Drug Therapy · For: Ventricular Tachycardia; Ventricular Arrhythmia
Sites: Ottawa, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.
Ortiz M, Martín A, Arribas F, et al. · Eur Heart J 2017 · Comparative Study, Multicenter Study
- External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Kukendrarajah K, Ahmad M, Carrington M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Ventricular tachyarrhythmias (out-of-hospital cardiac arrests).
Lang ES, Browning K · BMJ Clin Evid 2010 · Systematic Review
- Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial.
Stiell IG, Taljaard M, Eagles D, et al. · BMJ 2025 · Randomized Controlled Trial, Multicenter Study
- Drug treatment for myotonia.
Spillane J, Trip J, Drost G, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Markey GC, Salter N, Ryan J · J Emerg Med 2018 · Meta-Analysis, Systematic Review
Sponsor: Apothecon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.